Reviewing Data on Lenvatinib plus Pembrolizumab Combination Treatment for Advanced Renal Cell Carcinoma

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Rana McKay, MD, and Tom Powles, MBBS, MRCP, MD, highlight key data from the CLEAR trial and offer their overall opinions on the combination of lenvatinib plus pembrolizumab for the treatment of renal cell carcinoma [RCC].

Experts discuss how data from the CLEAR trial affects the management of advanced renal cell carcinoma in their clinical practices.

Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.

Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.

Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

A look at the current unmet needs in front-line renal cell carcinoma treatment.

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.

Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.

A look at how to best sequence therapies for renal cell carcinoma from the front-line setting on.

Drs Thomas Hutson and Scott Tykodi explain when to consider a debulking surgery for patients with renal cell carcinoma.

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.

Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.

A panel of oncologists reviews a publication by Robert J. Motzer, MD, and colleagues on data from the CLEAR trial examining lenvatinib plus either pembrolizumab or everolimus for advanced renal cell carcinoma.